Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPA1 | O75762 | 11/20 | 0.55 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.49 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.49 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.44 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.44 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.40 |
| ▸ | FBP1 | P09467 | 1/20 | 0.40 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3602792 | 1.00 | TRPA1 (0.55) | TRPA1ABCB11SIGMAR1MEN1LMNA | |
| SCHEMBL14419183 | 0.83 | TRPA1 (0.58) | TRPA1ABCB11SIGMAR1MEN1LMNA | |
| SCHEMBL14604979 | 0.83 | TRPA1 (0.58) | TRPA1ABCB11SIGMAR1MEN1LMNA | |
| SCHEMBL3593425 | 0.81 | TRPA1 (0.51) | TRPA1ABCB11SIGMAR1MEN1LMNA | |
| SCHEMBL10988524 | 0.81 | TRPA1 (0.47) | TRPA1ABCB11SIGMAR1MEN1LMNA | |
| SCHEMBL10988520 | 0.81 | TRPA1 (0.47) | TRPA1ABCB11SIGMAR1MEN1LMNA | |
| SCHEMBL10986454 | 0.81 | TRPA1 (0.47) | TRPA1ABCB11SIGMAR1MEN1LMNA | |
| SCHEMBL3593427 | 0.81 | TRPA1 (0.51) | TRPA1ABCB11SIGMAR1MEN1LMNA | |
| SCHEMBL10986457 | 0.81 | TRPA1 (0.47) | TRPA1ABCB11SIGMAR1MEN1LMNA | |
| SCHEMBL1758330 | 0.80 | CYP2A6 (0.41) | MAPTCYP2C9CYP2C19KMT2ANPSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1637527-B1 | CANNABINOID RECEPTOR MODULATOR | TAKEDA PHARMACEUTICAL (JP) | 2013-04-17 | — | — | EP | disclosed |
| US-20100240743-A1 | CANNABINOID RECEPTOR MODULATOR | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-09-23 | — | — | US | disclosed |
| US-7507841-B2 | Carbamoylamino-substituted 2,3-dihydro-benzofurans, indoles and benzothiophenes, e.g., (+)-N-((3R)-3-(4-isopropylphenyl)-4,6,7-trimethyl-2,3-dihydro-1-benzofuran-5-yl)-3,3-dimethylbutanamide; cerebrovascular disorders | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-03-24 | — | — | US | disclosed |
| US-20090023800-A1 | Cannabinoid receptor modulator | TAKEDA PHARMACEUTICAL COMPANY LIMITED | 2009-01-22 | — | — | US | disclosed |
| EP-1323716-B1 | PROMOTERS FOR THE PROLIFERATION AND DIFFERENTIATION OF STEM CELLS AND/OR NEURON PRECURSOR CELLS | TAKEDA PHARMACEUTICAL (JP) | 2009-01-14 | — | — | EP | disclosed |
| US-20090012081-A1 | Agents for promoting the proliferation or differentiation of stem cells or neural progenitor cells | TAKEDA PHARMACEUTICAL COMPANY LTD. (JP) | 2009-01-08 | — | — | US | disclosed |
| US-7465815-B2 | Cannabinoid receptor modulator | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2008-12-16 | — | — | US | disclosed |
| US-7456162-B2 | Benzofuran derivatives, their production and use | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2008-11-25 | — | — | US | disclosed |
| US-20080021087-A1 | Cannabinoid receptor modulator | TAKEDA PHARMACEUTICAL COMPANY LIMITED | 2008-01-24 | — | — | US | disclosed |
| US-20070099990-A1 | Cannabinoid receptor modulator | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2007-05-03 | — | — | US | disclosed |
| US-6479536-B1 | Benzofuran derivatives, process for the preparation of the same and uses thereof | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 2002-11-12 | — | — | US | disclosed |
| US-20020160996-A1 | Benzofuran derivatives, their production and use | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2002-10-31 | — | — | US | disclosed |
| EP-1136477-A1 | BENZOFURAN DERIVATIVES, PROCESS FOR THE PREPARATION OF THE SAME AND USES THEREOF | Takeda Chemical Industries, Ltd. (JP) | 2001-09-26 | — | — | EP | disclosed |
| US-4495196-A | Antiinflammatory 4,5-diaryl-α-polyfluoroalkyl-1H-pyrrole-2-methanols and method for use thereof | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 1985-01-22 | — | — | US | disclosed |
| EP-0038536-B1 | ANTIINFLAMMATORY 4,5-DIARYL-ALPHA-(POLYFLUOROALKYL)-1H-PYRROLE-2-METHANAMINES | E.I. DU PONT DE NEMOURS AND COMPANY (US) | 1984-02-01 | — | — | EP | disclosed |
| US-4335136-A | Anti-inflammatory 4,5-diaryl-α-(polyfluoroalkyl)-1H-pyrrole-2-methanamines | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 1982-06-15 | — | — | US | disclosed |
| EP-0038997-A1 | Anti-inflammatory 4,5-diaryl-alpha, alpha-bis(polyfluoroalkyl)-1H-pyrrole-2-methane thiols, processes for their preparation and pharmaceutical compositions containing them | E.I. DU PONT DE NEMOURS AND COMPANY (US) | 1981-11-04 | — | — | EP | disclosed |
| EP-0038536-A1 | Antiinflammatory 4,5-diaryl-alpha-(polyfluoroalkyl)-1H-pyrrole-2-methanamines | E.I. DU PONT DE NEMOURS AND COMPANY (US) | 1981-10-28 | — | — | EP | disclosed |
| US-4267190-A | AND METHOD OF ADMINISTERING TO MAMMALS FOR TREATMENT OF ARTHRITIS | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 1981-05-12 | — | — | US | disclosed |
| EP-0025884-A1 | 4,5-Diaryl-alpha-polyfluoroalkyl-1H-pyrrole-2-methanols and 1-(4,5-diaryl-1H-pyrrol-2-yl)-polyfluoroalkanones, processes for preparing them and pharmaceutical compositions | E.I. DU PONT DE NEMOURS AND COMPANY (US) | 1981-04-01 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090012081-A1 | Agents for promoting the proliferation or differentiation of stem cells or neural progenitor cells | NES, MKI67, CCNO | TRPA1 3644/4885ABCB11 1289/4885SIGMAR1 2628/4885 |
| US-20100240743-A1 | CANNABINOID RECEPTOR MODULATOR | CNR1, CNR2, GPR18 | TRPA1 126/4885ABCB11 1719/4885SIGMAR1 35/4885 |
| US-20080021087-A1 | Cannabinoid receptor modulator | CNR1, CNR2, GPR18 | TRPA1 126/4885ABCB11 1719/4885SIGMAR1 35/4885 |
| US-20090023800-A1 | Cannabinoid receptor modulator | CNR1, CNR2, GPR18 | TRPA1 126/4885ABCB11 1719/4885SIGMAR1 35/4885 |
| US-20020160996-A1 | Benzofuran derivatives, their production and use | PARK7, WDR1, WHR1 | TRPA1 667/4885ABCB11 443/4885SIGMAR1 1022/4885 |
| US-20070099990-A1 | Cannabinoid receptor modulator | CNR1, CNR2, GPR18 | TRPA1 126/4885ABCB11 1719/4885SIGMAR1 35/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.